Cargando…
A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer
Prostate cancer (PCa) is the second most common malignancy in men, but its exact pathogenetic mechanisms remain unclear. This study explores the effect of enhancer RNAs (eRNAs) in PCa. Firstly, we screened eRNAs and eRNA -driven genes from The Cancer Genome Atlas (TCGA) database, which are related t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276043/ https://www.ncbi.nlm.nih.gov/pubmed/34267780 http://dx.doi.org/10.3389/fgene.2021.676845 |
_version_ | 1783721835884445696 |
---|---|
author | Fan, Shuaishuai Wang, Zheng Zhao, Li Zhao, ChenHui Yuan, DaJiang Wang, Jingqi |
author_facet | Fan, Shuaishuai Wang, Zheng Zhao, Li Zhao, ChenHui Yuan, DaJiang Wang, Jingqi |
author_sort | Fan, Shuaishuai |
collection | PubMed |
description | Prostate cancer (PCa) is the second most common malignancy in men, but its exact pathogenetic mechanisms remain unclear. This study explores the effect of enhancer RNAs (eRNAs) in PCa. Firstly, we screened eRNAs and eRNA -driven genes from The Cancer Genome Atlas (TCGA) database, which are related to the disease-free survival (DFS) of PCa patients;. screening methods included bootstrapping, Kaplan–Meier (KM) survival analysis, and Pearson correlation analysis. Then, a risk score model was established using multivariate Cox analysis, and the results were validated in three independent cohorts. Finally, we explored the function of eRNA-driven genes through enrichment analysis and analyzed drug sensitivity on datasets from the Genomics of Drug Sensitivity in Cancer database. We constructed and validated a robust prognostic gene signature involving three eRNA-driven genes namely MAPK15, ZNF467, and MC1R. Moreover, we evaluated the function of eRNA-driven genes associated with tumor microenvironment (TME) and tumor mutational burden (TMB), and identified remarkable differences in drug sensitivity between high- and low-risk groups. This study identified a prognostic gene signature, which provides new insights into the role of eRNAs and eRNA-driven genes while assisting clinicians to determine the prognosis and appropriate treatment options for patients with PCa. |
format | Online Article Text |
id | pubmed-8276043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82760432021-07-14 A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer Fan, Shuaishuai Wang, Zheng Zhao, Li Zhao, ChenHui Yuan, DaJiang Wang, Jingqi Front Genet Genetics Prostate cancer (PCa) is the second most common malignancy in men, but its exact pathogenetic mechanisms remain unclear. This study explores the effect of enhancer RNAs (eRNAs) in PCa. Firstly, we screened eRNAs and eRNA -driven genes from The Cancer Genome Atlas (TCGA) database, which are related to the disease-free survival (DFS) of PCa patients;. screening methods included bootstrapping, Kaplan–Meier (KM) survival analysis, and Pearson correlation analysis. Then, a risk score model was established using multivariate Cox analysis, and the results were validated in three independent cohorts. Finally, we explored the function of eRNA-driven genes through enrichment analysis and analyzed drug sensitivity on datasets from the Genomics of Drug Sensitivity in Cancer database. We constructed and validated a robust prognostic gene signature involving three eRNA-driven genes namely MAPK15, ZNF467, and MC1R. Moreover, we evaluated the function of eRNA-driven genes associated with tumor microenvironment (TME) and tumor mutational burden (TMB), and identified remarkable differences in drug sensitivity between high- and low-risk groups. This study identified a prognostic gene signature, which provides new insights into the role of eRNAs and eRNA-driven genes while assisting clinicians to determine the prognosis and appropriate treatment options for patients with PCa. Frontiers Media S.A. 2021-06-29 /pmc/articles/PMC8276043/ /pubmed/34267780 http://dx.doi.org/10.3389/fgene.2021.676845 Text en Copyright © 2021 Fan, Wang, Zhao, Zhao, Yuan and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Fan, Shuaishuai Wang, Zheng Zhao, Li Zhao, ChenHui Yuan, DaJiang Wang, Jingqi A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer |
title | A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer |
title_full | A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer |
title_fullStr | A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer |
title_full_unstemmed | A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer |
title_short | A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer |
title_sort | robust prognostic gene signature based on ernas-driven genes in prostate cancer |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276043/ https://www.ncbi.nlm.nih.gov/pubmed/34267780 http://dx.doi.org/10.3389/fgene.2021.676845 |
work_keys_str_mv | AT fanshuaishuai arobustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer AT wangzheng arobustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer AT zhaoli arobustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer AT zhaochenhui arobustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer AT yuandajiang arobustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer AT wangjingqi arobustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer AT fanshuaishuai robustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer AT wangzheng robustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer AT zhaoli robustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer AT zhaochenhui robustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer AT yuandajiang robustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer AT wangjingqi robustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer |